Normally, the human immune system cannot recognize cytokines on its own because during early development it loses the ability to attack them. But sometimes it is desirable to temporarily harness the immune system to recognize...

Neovacs S.A. Paris, France Technology: Stimulating human polyclonal antibody response against cytokines and retroviral proteins Disease focus: AIDS, cancer, autoimmune disease, allergy Clinical status: Phase I/II Founded: Restarted 2003 by Truffle Ventures Corporate partners: Aventis...

Neovacs SA , Paris, France Business: Antibodies, Infectious diseases Appointed: Philippe Pouletty, general partner of Truffle Ventures, as chairman; Jean-Jacques Bertrand, former chairman and CEO of Aventis Pasteur SA WIR Staff Infectious...

The doomsday mood in European biotech is lifting. Since the market bottom in March, BioCentury's European and London indices now are tracking the upswing in U.S. biotech stocks. The BioCentury 100 Index, which consists primarily...